LGVN - Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) | Benzinga
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company's CLEAR MIND Phase 2a study results. CLEAR-MIND is a Phase 2a randomized clinical trial evaluating Lomecel-BTM in mild Alzheimer's Disease. In addition to the clinical study results, the Company has been accepted for a poster presentation at the 2024 Alzheimer's Association International Conference (AAIC), to be held July 28 – August 1, 2024 in Philadelphia, PA, USA and online.
"We are extremely excited to share the full study results of our CLEAR-MIND trial at the AAIC meeting this year, and have the opportunity to present at the leading forum for Alzheimer's disease clinical investigation," said Wa'el Hashad, CEO of Longeveron.
| Oral Presentation |
| Date: |
| Sunday, July 28, 2024 |
| Time: |
| 4:15pm – 5:45pm EDT |
| Session: |
| Featured Research Session, 1-32-FRS-B |
| Title: |
| "Results from a Phase 2a Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Lomecel-BTM in Mild Alzheimer's Disease Dementia" |
| Longeveron's Kevin N. Ramdas, MD, MPH, Director of Clinical Operations, was invited to chair this Featured Research Session. |
| Poster Presentation |
| Date: |
| Tuesday, July 30, 2024 |
| Time: |
| 7:30am – 4:15pm EDT |
| Session: |
| In-Person Posters Tuesday; Drug Development |
| Topic: |
| MRI Imaging results in the CLEAR MIND phase 2a clinical trial of Lomecel-BTM |
Longeveron previously announced top-line results for the CLEAR MIND Phase 2a clinical trial on October 5, 2023, and reported additional clinical data and imaging biomarker results from CLEAR MIND on December 20, 2023.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B™ an allogeneic Mesenchymal Stem Cell (MSC) formulation sourced from the bone marrow ...